Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results-Reference-Cited by-同舟云学术

Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results

Published:2023-07 Issue:5 Volume:24 Page:467-473
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Lococo Filippo^ORCID,Cancellieri Alessandra,Chiappetta Marco,Leonetti Alessandro,Cardillo Giuseppe,Zanelli Francesca,Mangiameli Giuseppe,Toschi Luca,Guggino Gianluca,Romano Francesco Jacopo,Leuzzi Giovanni,Proto Claudia,Spaggiari Lorenzo,De Marinis Filippo,Vita Emanuele,Ampollini Luca,Margaritora Stefano,Tiseo Marcello,Bria Emilio

Funder

Università Cattolica del Sacro Cuore

Boehringer Ingelheim

Ministero della Salute

AstraZeneca

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010